Aberdeen Group plc lowered its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report) by 67.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 210,659 shares of the company’s stock after selling 436,284 shares during the period. Aberdeen Group plc’s holdings in Oruka Therapeutics were worth $17,546,000 as of its most recent filing with the SEC.
Several other large investors also recently added to or reduced their stakes in the company. Nykredit A S bought a new stake in Oruka Therapeutics in the 2nd quarter valued at about $29,000. GAMMA Investing LLC lifted its holdings in Oruka Therapeutics by 201.6% during the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after purchasing an additional 250 shares during the last quarter. Orion Capital Management LLC purchased a new stake in Oruka Therapeutics during the second quarter valued at about $91,000. Sterling Capital Management LLC boosted its position in Oruka Therapeutics by 839.0% during the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock worth $138,000 after purchasing an additional 1,485 shares during the period. Finally, Royal Bank of Canada boosted its position in Oruka Therapeutics by 178.5% during the first quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock worth $155,000 after purchasing an additional 2,033 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.
Oruka Therapeutics Trading Down 2.9%
Shares of NASDAQ ORKA opened at $96.32 on Wednesday. Oruka Therapeutics, Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $115.51. The stock has a fifty day moving average of $89.85 and a 200-day moving average of $72.99.
Insider Buying and Selling
In other news, CEO Lawrence Klein sold 75,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the sale, the chief executive officer directly owned 925,580 shares in the company, valued at $84,996,011.40. This represents a 7.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the sale, the insider owned 31,771 shares in the company, valued at approximately $2,935,004.98. This represents a 20.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 197,950 shares of company stock worth $18,288,360 in the last 90 days. 23.49% of the stock is owned by company insiders.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. BTIG Research reaffirmed a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, November 10th. Finally, Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday, September 3rd. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $141.80.
Check Out Our Latest Stock Analysis on ORKA
Oruka Therapeutics Profile
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Further Reading
- Five stocks we like better than Oruka Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding ORKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oruka Therapeutics, Inc. (NASDAQ:ORKA – Free Report).
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
